Vistagen Therapeutics, Inc.

VTGN Nasdaq SEC CIK 1411685
Follow Vistagen Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q2 2027 USD · US GAAP
Revenue, last quarter $138K −46.5% vs same quarter last year
Net income −$10.7M +44.7% vs same quarter last year
EPS, diluted −$0.24 +55.6% vs same quarter last year
Operating cash flow −$12.2M +11.6% vs same quarter last year
Revenue by quarter
$234K
$244K
$258K
$303K
$465K
$1.5M
$138K
Q3 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27 Q2 27

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$80M−$60M−$40M−$20M$0$20MFY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearRevenueNet income
FY26$1.3M−$69.7M
FY25$486K−$51.4M
FY24$1.1M−$29.4M
FY23-−$59.2M
FY22$1.1M−$47.8M
FY21$1.1M−$17.9M
FY20$0−$20.8M
FY19-−$24.6M
FY18$0−$14.3M
FY17$1.3M−$10.3M
FY16$0−$47.2M
FY15-−$13.9M
FY14-−$3M
FY13$200.4K-
FY12$1.3M−$12.2M
MarginsShare of revenue
  • Operating margin
  • Net margin
−15000%−10000%−5000%0%FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearOperating marginNet margin
FY26−5683.7%−5491.9%
FY25−11517.1%−10579.8%
FY24−3103.5%−2759.6%
FY23--
FY22−4308.3%−4306.8%
FY21−1646.1%−1646.1%
FY20--
FY19--
FY18--
FY17−819.9%−820.4%
FY16--
FY15--
FY14--
FY13−3389.8%-
FY12−673.8%−909.7%
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearFree cash flow
FY26-
FY25-
FY24−$25.8M
FY23−$50.2M
FY22−$45.5M
FY21−$12.3M
FY20−$15.8M
FY19−$14.7M
FY18−$9.1M
FY17−$7.5M
FY16−$4.8M
FY15-
FY14-
FY13-
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Vistagen Therapeutics
  • Healthcare median
−15000%−10000%−5000%0%FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearVistagen TherapeuticsHealthcare median
FY26−5491.9%−11.1%
FY25−10579.8%−30.6%
FY24−2759.6%−47%
FY23-−58%
FY22−4306.8%−80.4%
FY21−1646.1%−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17−820.4%−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12−909.7%−29.1%